A phase I/II, double-blind, placebo-controlled study assessing the safety and efficacy of AVX-012 ophthalmic solution in subjects with mild-to-moderate dry eye syndrome

Trial Profile

A phase I/II, double-blind, placebo-controlled study assessing the safety and efficacy of AVX-012 ophthalmic solution in subjects with mild-to-moderate dry eye syndrome

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs AVX 012 (Primary)
  • Indications Dry eyes
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors AVX Pharma
  • Most Recent Events

    • 23 Oct 2017 Planned End Date changed from 1 Jan 2018 to 1 Oct 2018.
    • 23 Oct 2017 Planned primary completion date changed from 1 Oct 2017 to 1 May 2018.
    • 13 Jul 2017 According to an Avizorex Pharma media release, the phase II portion of this trial has been initiated.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top